<prompt> Ibrutinib drug is used in all except:Mantle cell lymphomaChronic lymphocytic leukemiaWaldenstroms macroglobulinemiaAML  <response>: Bruton tyrosine kinase BTK is a validated target for B cell malignancies. BTK inhibitor ibrutinib was approved in: - Chronic lymphocytic leukaemia- Mantle cell lymphoma- Waldenstroms macroglobulinemia NIB -drug ending with NIB are kinase inhibitor BRUT - Brutons tyrosine kinase inhibitor 